Months after $1.9B deal with Bristol Myers, Boston biotech cuts workers


The Boston-based startup blamed the layoffs on "a challenging biotech macroenvironment."

Previous U.S. Bank announces new CFO, chief administration officer
Next Argyle Restaurant to open at The Yards